Treats active duodenal ulcer. ANDA 201921, held by Natco Pharma. Lansoprazole.
As of Nov 21, 2026, ANDA 201921 (Lansoprazole), held by Natco Pharma, was first approved by FDA on Dec 18, 2012, with 5 approved supplements and 0 published complete response letters.
Lansoprazole delayed-release capsules are proton pump inhibitors (PPIs) indicated for the: Treatment of active duodenal ulcer in adults. Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. Maintenance of healed duodenal ulcers in adults. Treatment of active benign gastric ulcer in adults. Healing of non steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. Risk reduction of NSAID-associated gastric ulcer in adults. Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older. Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 18, 2012 | Original application | Approved | None posted |
| Lansoprazole15MG ยท capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| Lansoprazole30MG ยท capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| May 2, 2024 | Supplement 8Labeling ยท Standard review | Approved | None posted |
| Jun 3, 2019 | Supplement 6Labeling ยท Standard review | Approved | None posted |
| Sep 26, 2017 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Sep 26, 2017 | Supplement 3Labeling ยท Standard review | Approved | None posted |
| Mar 16, 2015 | Supplement 1Labeling ยท Standard review | Approved | None posted |
| Dec 18, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters